{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:47:43Z","timestamp":1780458463171,"version":"3.54.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000199","name":"U.S. Department of Agriculture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000199","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["272201400006C"],"award-info":[{"award-number":["272201400006C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Influenza virus infections are a major cause of respiratory disease in humans. Neuraminidase inhibitors (NAIs) are the primary antiviral medication used to treat ongoing influenza infections. However, NAIs are not always effective for controlling virus shedding and lung inflammation. Other concerns are the emergence of NAI-resistant virus strains and the risk of side effects, which are occasionally severe. Consequently, additional anti-influenza therapies to replace or combine with NAIs are desirable. Here, we compared the efficacy of the NAI oseltamivir with the invariant natural killer T (iNKT) cell superagonist, \u03b1-galactosylceramide (\u03b1-GalCer), which induces innate immune responses that inhibit influenza virus replication in mouse models. We show that oseltamivir reduced lung lesions and lowered virus titers in the upper respiratory tract of pigs infected with A\/California\/04\/2009 (CA04) pandemic H1N1pdm09. It also reduced virus transmission to influenza-na\u00efve contact pigs. In contrast, \u03b1-GalCer had no impact on virus replication, lung disease, or virus transmission, even when used in combination with oseltamivir. This is significant as iNKT-cell therapy has been studied as an approach for treating humans with influenza.<\/jats:p>","DOI":"10.3389\/fvets.2022.999507","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:57:11Z","timestamp":1666263431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of oseltamivir and \u03b1-galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus"],"prefix":"10.3389","volume":"9","author":[{"given":"Darling Melany de C.","family":"Madrid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca L.","family":"Artiaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian K.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Castleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lednicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen A.","family":"Richt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Driver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(18)30496-X","article-title":"Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017","volume":"7","author":"Troeger","year":"2019","journal-title":"Lancet Respir Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"556674","DOI":"10.3389\/fvets.2020.556674","article-title":"Financial analysis of herd status and vaccination practices for porcine reproductive and respiratory syndrome virus, swine influenza virus, and Mycoplasma hyopneumoniae in Farrow-to-Finish pig farms using a bio-economic simulation model","volume":"7","author":"Calder\u00f3n D\u00edaz","year":"2020","journal-title":"Front Vet Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch Intern Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/irv.12085","article-title":"Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies","volume":"7","author":"Santesso","year":"2013","journal-title":"Influenza Other Respir Viruses."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA."},{"key":"B12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/ilar\/ily009","article-title":"Animal models for influenza A virus infection incorporating the involvement of innate host defenses: enhanced translational value of the porcine model","volume":"59","author":"Starb\u00e6k","year":"2018","journal-title":"ILAR J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-immunol-032414-112008","article-title":"The immunology of CD1- and MR1-restricted T cells","volume":"34","author":"Mori","year":"2016","journal-title":"Annu Rev Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00441-010-1023-3","article-title":"Invariant natural killer T cells: bridging innate and adaptive immunity","volume":"343","author":"Van Kaer","year":"2011","journal-title":"Cell Tissue Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1189\/jlb.0411184","article-title":"Pivotal Advance: invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection","volume":"91","author":"Kok","year":"2012","journal-title":"J Leukoc Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.virol.2010.08.030","article-title":"IFN-\u03b3 production downstream of NKT cell activation in mice infected with influenza virus enhances the cytolytic activities of both NK cells and viral antigen-specific CD8+ T cells","volume":"407","author":"Ishikawa","year":"2010","journal-title":"Virology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/eji.200738017","article-title":"Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection","volume":"38","author":"Ho","year":"2008","journal-title":"Eur J Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1128\/AAC.00368-10","article-title":"In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models","volume":"54","author":"Lin","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.4049\/jimmunol.1801171","article-title":"Next generation sequencing of the Pig \u03b1\u03b2 TCR repertoire identifies the porcine invariant NKT cell receptor","volume":"202","author":"Yang","year":"2019","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"23593","DOI":"10.1038\/srep23593","volume":"6","author":"Artiaga","year":"2016","journal-title":"Sci Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"37999","DOI":"10.1038\/srep37999","article-title":"Rapid control of pandemic H1N1 influenza by targeting NKT-cells","volume":"6","author":"Artiaga","year":"2016","journal-title":"Sci Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"103843","DOI":"10.1016\/j.dci.2020.103843","article-title":"Unaltered influenza disease outcomes in swine prophylactically treated with \u03b1-galactosylceramide","volume":"114","author":"Gu","year":"2021","journal-title":"Dev Comp Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1128\/JVI.79.12.7535-7543.2005","article-title":"Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs","volume":"79","author":"Sol\u00f3rzano","year":"2005","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1164\/rccm.200608-1113OC","article-title":"Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease","volume":"175","author":"Demedts","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.4049\/jimmunol.1500747","article-title":"Clusterin modulates allergic airway inflammation by attenuating CCL20-mediated dendritic cell recruitment","volume":"196","author":"Hong","year":"2016","journal-title":"J Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/nri1249","article-title":"Taking our breath away: dendritic cells in the pathogenesis of asthma","volume":"3","author":"Lambrecht","year":"2003","journal-title":"Nat Rev Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e61597","DOI":"10.1371\/journal.pone.0061597","article-title":"Efficacy of influenza vaccination and tamiflu\u00ae treatment\u2013comparative studies with Eurasian Swine influenza viruses in pigs","volume":"8","author":"Duerrwald","year":"2013","journal-title":"PLoS ONE."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1086\/586711","article-title":"Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model","volume":"197","author":"Boltz","year":"2008","journal-title":"J Infect Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s0166-3542(97)00065-x","article-title":"Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor","volume":"37","author":"Sidwell","year":"1998","journal-title":"Antiviral Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e94090","DOI":"10.1371\/journal.pone.0094090","article-title":"Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir","volume":"9","author":"Marriott","year":"2014","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.antiviral.2011.05.008","article-title":"Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets","volume":"91","author":"Govorkova","year":"2011","journal-title":"Antiviral Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/600383","article-title":"Viral loads and duration of viral shedding in adult patients hospitalized with influenza","volume":"200","author":"Lee","year":"2009","journal-title":"J Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/s0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase inhibitor flu treatment investigator group","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.virol.2015.06.020","article-title":"Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets","volume":"484","author":"Belser","year":"2015","journal-title":"Virology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1008395","DOI":"10.1371\/journal.ppat.1008395","article-title":"Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/jac\/dku146","article-title":"Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact","volume":"69","author":"Oh","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US oral neuraminidase study group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.lfs.2011.12.014","article-title":"Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A\/California\/04\/2009 (H1N1)","volume":"90","author":"Zarogiannis","year":"2012","journal-title":"Life Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e02561","DOI":"10.1128\/AAC.02561-19","article-title":"Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model","volume":"64","author":"Nguyen","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1073\/pnas.0701849104","article-title":"Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene","volume":"104","author":"Grimm","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"10818","DOI":"10.1128\/JVI.01116-07","article-title":"The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses","volume":"81","author":"Tumpey","year":"2007","journal-title":"J Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.vetmic.2016.05.013","article-title":"An in-depth comparison of the porcine, murine and human inflammasomes; lessons from the porcine genome and transcriptome","volume":"202","author":"Dawson","year":"2017","journal-title":"Vet Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vetimm.2014.09.006","article-title":"Adjuvant effects of therapeutic glycolipids administered to a cohort of NKT cell-diverse pigs","volume":"162","author":"Artiaga","year":"2014","journal-title":"Vet Immunol Immunopathol."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.999507\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T13:50:46Z","timestamp":1666360246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.999507\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":47,"alternative-id":["10.3389\/fvets.2022.999507"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2022.999507","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"999507"}}